US20030235908A1
(en)
*
|
2000-02-24 |
2003-12-25 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US20030119185A1
(en)
|
2000-02-24 |
2003-06-26 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
US6977072B2
(en)
*
|
2000-10-27 |
2005-12-20 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy for immune suppressed patients
|
US20020055759A1
(en)
*
|
2000-11-06 |
2002-05-09 |
Shibuya Terry Y. |
Bioactive surgical suture
|
CA2430816C
(en)
*
|
2000-12-07 |
2012-05-15 |
Altana Pharma Ag |
Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
|
US7745140B2
(en)
*
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
US7638326B2
(en)
*
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
EP2034009B1
(de)
*
|
2002-02-08 |
2014-01-15 |
Life Technologies Corporation |
Zusammensetzungen und Verfahren zur Wiederherstellung der Immunreaktivität in Patienten mit immunologischen Defekten basierend auf CD3/CD28 costimulation
|
CN100379852C
(zh)
*
|
2002-02-08 |
2008-04-09 |
埃克斯西特治疗公司 |
用于在免疫缺陷患者体内恢复免疫响应的组合物和方法
|
DE10212108A1
(de)
*
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
ES2397319T3
(es)
|
2002-03-25 |
2013-03-06 |
Takara Bio Inc. |
Proceso para producir linfocitos citotóxicos
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
EP1539929B1
(de)
*
|
2002-06-28 |
2013-04-10 |
Life Technologies Corporation |
Verfahren zur wiederherstellung des immunrepertoirs in patienten mit immunologischen defekten in verbindung mit autoimmunität sowie transplantation von organen oder hämatopoetischen stammzellen
|
DE10230223A1
(de)
*
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
CA2505394C
(en)
*
|
2002-11-07 |
2014-05-13 |
University Of Chicago |
Human stem cell materials and methods
|
CN1230531C
(zh)
*
|
2002-12-09 |
2005-12-07 |
清华大学 |
从样品中分离细胞粒子的方法
|
WO2004075855A2
(en)
|
2003-02-26 |
2004-09-10 |
Biomed Solutions, Llc |
Process for in vivo treatment of specific biological targets in bodily fluid
|
JP2006524991A
(ja)
*
|
2003-05-08 |
2006-11-09 |
エクサイト セラピーズ インコーポレーティッド |
抗原特異的t細胞の作製および単離の方法
|
US7435592B2
(en)
*
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
US20110142887A1
(en)
*
|
2009-12-15 |
2011-06-16 |
Immunovative Therapies Ltd. |
Methods and compositions for liquidation of tumors
|
US20070025961A1
(en)
|
2003-06-03 |
2007-02-01 |
Kenzo Bamba |
Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
|
US8927273B2
(en)
|
2003-08-22 |
2015-01-06 |
Takara Bio Inc. |
Process for producing cytotoxic lymphocytes
|
CA2539716A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Xcyte Therapies, Inc. |
Compositions and methods to accelerate hematologic recovery
|
KR101111231B1
(ko)
*
|
2003-09-25 |
2012-02-17 |
비바리스 |
마이크로 웰 어레이 칩 및 그 제조방법
|
US8465453B2
(en)
*
|
2003-12-03 |
2013-06-18 |
Mayo Foundation For Medical Education And Research |
Kits, apparatus and methods for magnetically coating medical devices with living cells
|
US20090118817A1
(en)
*
|
2005-06-16 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
Magnetic Medical Apparatus, Kits, and Methods
|
CN1953767B
(zh)
*
|
2004-01-08 |
2011-03-16 |
加利福尼亚大学董事会 |
调节t细胞抑制自身免疫
|
SI2573166T1
(sl)
|
2004-02-26 |
2016-09-30 |
Immunovative Therapies, Ltd. |
Metode za pripravo T-celic za celično terapijo
|
US7592431B2
(en)
*
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
EP3363907A1
(de)
|
2004-05-27 |
2018-08-22 |
The Trustees of the University of Pennsylvania |
Neue künstliches antigen präsentierende zellen und verwendungen dafür
|
WO2007011707A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Polymer coatings containing drug powder of controlled morphology
|
EP1916302A4
(de)
|
2005-08-17 |
2009-10-21 |
Takara Bio Inc |
Verfahren zur herstellung von lymphozyten
|
KR101138868B1
(ko)
|
2005-08-23 |
2012-05-14 |
삼성전자주식회사 |
생분자의 다이일렉트릭 특성을 나노입자로 향상시켜표적생분자만을 선택적으로 분리하는 dep 및 나노입자를이용한 표적생분자분리방법
|
US9388382B2
(en)
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
ES2540059T3
(es)
|
2006-04-26 |
2015-07-08 |
Micell Technologies, Inc. |
Recubrimientos que contienen múltiples fármacos
|
WO2008023874A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Binex Co., Ltd. |
Manufacturing method of activated lymphocytes for immunotherapy
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
CA2666789C
(en)
|
2006-10-18 |
2016-11-22 |
Yong Zhao |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
CN101374538A
(zh)
*
|
2006-10-30 |
2009-02-25 |
吉诺米克斯股份有限公司 |
损伤组织的功能再生促进药物
|
US11426494B2
(en)
*
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
US20090062237A1
(en)
*
|
2007-06-15 |
2009-03-05 |
Mayo Foundation For Medical Education And Research |
Evaluating immune competence
|
US7816135B2
(en)
*
|
2007-07-05 |
2010-10-19 |
Becton, Dickinson And Company |
Method of analyzing lymphocytes
|
AU2008329741B2
(en)
|
2007-11-28 |
2013-09-12 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
US20090259251A1
(en)
*
|
2008-04-11 |
2009-10-15 |
Cohen Matthew D |
Loop suture
|
EP2276850B9
(de)
*
|
2008-04-14 |
2013-10-30 |
IRX Therapeutics, Inc. |
Irx-2-modifziertes herstellungsverfahren
|
AU2009240885A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Genomix Co., Ltd. |
Pharmaceutical agent for promoting the functional regeneration of damaged tissue
|
KR20160070169A
(ko)
|
2008-04-30 |
2016-06-17 |
가부시키가이샤 제노믹스 |
생체내 기능적 세포의 고효율 채취법
|
RU2519714C2
(ru)
*
|
2008-04-30 |
2014-06-20 |
Дженомикс Ко., Лтд. |
Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
|
ES2679043T3
(es)
|
2009-05-15 |
2018-08-21 |
Irx Therapeutics, Inc. |
Inmunoterapia de vacuna
|
EP3633024A1
(de)
*
|
2009-06-11 |
2020-04-08 |
Minerva Biotechnologies Corporation |
Verfahren zur kultivierung von stammzellen und vorläuferzellen
|
CA2776613A1
(en)
*
|
2009-10-07 |
2011-04-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N |
Devices, systems and methods for cell modification
|
CA2778759A1
(en)
|
2009-10-28 |
2011-05-05 |
Genomix Co., Ltd. |
Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
|
US9333238B2
(en)
|
2009-12-08 |
2016-05-10 |
Irx Therapeutics, Inc. |
Method of immunotherapy for treament of human papillomavirus infection
|
US8968362B2
(en)
|
2010-04-08 |
2015-03-03 |
Covidien Lp |
Coated looped suture
|
AU2011287108B2
(en)
*
|
2010-08-06 |
2014-08-28 |
Canine-Lab.Inc. |
Immunological function enhancing agent
|
CN106220739A
(zh)
|
2010-12-09 |
2016-12-14 |
宾夕法尼亚大学董事会 |
嵌合抗原受体‑修饰的t细胞治疗癌症的用途
|
BR112013018311A2
(pt)
|
2011-01-18 |
2017-03-21 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
|
CA2834255C
(en)
|
2011-04-26 |
2021-11-02 |
Genomix Co., Ltd. |
Peptide for inducing regeneration of tissue and use thereof
|
SG194753A1
(en)
|
2011-05-03 |
2013-12-30 |
Immunovative Therapies Ltd |
Induction of il-12 using immunotherapy
|
HUE034995T2
(en)
|
2011-05-03 |
2018-05-02 |
Immunovative Therapies Ltd |
A method for treating biological agents comprising living cells
|
TR201808740T4
(tr)
*
|
2011-06-29 |
2018-07-23 |
Cellestis Ltd |
Arttırılmış duyarlılığa sahip hücre aracılı bir immün yanıt tahlili.
|
US20150030619A1
(en)
*
|
2011-09-06 |
2015-01-29 |
The Trustees Of Columbia University In The City Of New York |
Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity
|
WO2013036819A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Dana Farber Cancer Institute, Inc. |
Methods of increasing the number of target cells recovered from a fluid sample
|
MX2014003176A
(es)
|
2011-09-16 |
2015-08-05 |
Univ Pennsylvania |
Celulas t diseñadas mediante arn para el tratamiento de cancer.
|
WO2013044225A1
(en)
|
2011-09-22 |
2013-03-28 |
The Trustees Of The University Of Pennsylvania |
A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
WO2013126733A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
JP2015513399A
(ja)
|
2012-02-22 |
2015-05-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌の治療のために有用なt細胞の存続的集団を作製するための組成物および方法
|
AU2013222284A1
(en)
|
2012-02-22 |
2014-08-07 |
The Trustees Of The University Of Pennsylvania |
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
|
MA37681B2
(fr)
|
2012-05-25 |
2020-07-29 |
Cellectis |
Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
CN102718869B
(zh)
*
|
2012-06-06 |
2014-08-06 |
西安交通大学 |
一种固定化呈递免疫共刺激分子的微球及其制备方法
|
US9765156B2
(en)
|
2012-07-13 |
2017-09-19 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
BR112015000505A2
(pt)
|
2012-07-13 |
2017-06-27 |
Univ Pennsylvania |
método de analisar uma célula t geneticamente modificada para detectar um contaminante
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
CN104769103B
(zh)
|
2012-09-04 |
2018-06-08 |
塞勒克提斯公司 |
多链嵌合抗原受体和其用途
|
EP2711418B1
(de)
|
2012-09-25 |
2017-08-23 |
Miltenyi Biotec GmbH |
Verfahren zur polyklonalen Stimulation von T-Zellen durch flexible Nanomatricen
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
TR201807769T4
(tr)
|
2012-10-25 |
2018-06-21 |
Genomix Co Ltd |
HMGB1 fragmanı kullanılarak spinal kord yaralanmasının tedavi edilmesine yönelik yeni yöntem.
|
AU2013335684B2
(en)
|
2012-10-25 |
2017-06-29 |
Osaka University |
Novel method for treating cardiac infarction using HMGB1 fragment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
UY35340A
(es)
|
2013-02-20 |
2014-09-30 |
Novartis Ag |
Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
JP6632072B2
(ja)
|
2013-03-14 |
2020-01-15 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ナノスケール人工抗原提示細胞
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
US10238690B2
(en)
|
2013-03-15 |
2019-03-26 |
Celgene Corporation |
Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
WO2014184744A1
(en)
|
2013-05-13 |
2014-11-20 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
FI3546572T3
(fi)
|
2013-05-13 |
2024-05-06 |
Cellectis |
Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja
|
US9890393B2
(en)
|
2013-05-29 |
2018-02-13 |
Cellectis |
Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CN105658784B
(zh)
|
2013-12-18 |
2018-12-11 |
东洋制罐集团控股株式会社 |
培养容器、淋巴细胞的培养方法、培养容器的制造方法和固相化装置
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
CA2934073A1
(en)
|
2013-12-20 |
2015-06-25 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
US10836998B2
(en)
|
2014-02-14 |
2020-11-17 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
ES2782125T3
(es)
|
2014-03-11 |
2020-09-10 |
Cellectis |
Método para generar linfocitos T compatibles para trasplante alogénico
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3593812A3
(de)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Behandlung von krebs mithilfe eines chimären antigenrezeptors
|
PL3119807T3
(pl)
|
2014-03-19 |
2019-09-30 |
Cellectis |
Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
|
IL293603B2
(en)
|
2014-04-07 |
2024-03-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
WO2015155341A1
(en)
|
2014-04-11 |
2015-10-15 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
HUE048898T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
MND promoter kiméra antigén receptorok
|
HUE049514T2
(hu)
*
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
CA2947646A1
(en)
|
2014-05-02 |
2015-11-05 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
KR102485855B1
(ko)
|
2014-06-06 |
2023-01-09 |
2세븐티 바이오, 인코포레이티드 |
개선된 t 세포 조성물
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
AU2015292590B2
(en)
|
2014-07-24 |
2020-01-16 |
2Seventy Bio, Inc. |
BCMA chimeric antigen receptors
|
CA2950381C
(en)
|
2014-07-29 |
2021-02-23 |
Cellectis |
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
|
JP2017522893A
(ja)
|
2014-07-31 |
2017-08-17 |
セレクティスCellectis |
Ror1特異的多重鎖キメラ抗原受容体
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
RU2764074C2
(ru)
|
2014-08-28 |
2022-01-13 |
Байоатла, Ллк |
Условно активные химерные антигенные рецепторы для модифицированных т-клеток
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
WO2016033690A1
(en)
*
|
2014-09-04 |
2016-03-10 |
Stemcell Technologies Inc. |
Soluble antibody complexes for t cell or nk cell activation and expansion
|
CA2959694C
(en)
|
2014-09-04 |
2023-11-21 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
KR20210032011A
(ko)
|
2014-09-17 |
2021-03-23 |
더 존스 홉킨스 유니버시티 |
항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
DK3230321T3
(da)
|
2014-12-12 |
2019-10-28 |
Bluebird Bio Inc |
Kimære bcma-antigenreceptorer
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
EP3757211A1
(de)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
BR112017015453A2
(pt)
|
2015-01-26 |
2018-01-23 |
Cellectis |
células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
BR112017018224A2
(pt)
|
2015-03-11 |
2018-04-17 |
Cellectis |
métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
|
JP2018518152A
(ja)
|
2015-03-27 |
2018-07-12 |
ユニバーシティ オブ サザン カリフォルニア |
充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療
|
SG10201913158PA
(en)
|
2015-04-03 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
RU2021121771A
(ru)
|
2015-04-08 |
2022-01-12 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
|
WO2016166630A1
(en)
|
2015-04-13 |
2016-10-20 |
Pfizer Inc. |
Chimeric antigen receptors targeting b-cell maturation antigen
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US20180117155A1
(en)
|
2015-04-25 |
2018-05-03 |
The General Hospital Corporation |
Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
CA2984677C
(en)
|
2015-05-01 |
2022-05-17 |
The Regents Of The University Of California |
Glycan-dependent immunotherapeutic molecules
|
CN114107197A
(zh)
*
|
2015-05-13 |
2022-03-01 |
泰尔茂比司特公司 |
细胞扩增
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
AR104718A1
(es)
|
2015-05-20 |
2017-08-09 |
Cellectis |
Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
|
RU2020132040A
(ru)
|
2015-05-20 |
2020-10-12 |
Те Брод Инститьют Инк. |
Общие неоантигены
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
WO2016197064A1
(en)
|
2015-06-04 |
2016-12-08 |
Epstein Alan L |
Lym-1 and lym-2 targeted car cell immunotherapy
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
AU2016301195B2
(en)
|
2015-08-06 |
2022-09-01 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
|
EP3331913A1
(de)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
|
JP2018522907A
(ja)
|
2015-08-11 |
2018-08-16 |
セレクティスCellectis |
Cd38抗原を標的とするためおよびcd38遺伝子を不活化するために操作された、免疫療法用の細胞
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3337891B1
(de)
*
|
2015-08-21 |
2023-06-07 |
Mayo Foundation for Medical Education and Research |
Verfahren und materialien zur expansion von antigenspezifischen t-zellen in kultur
|
US11279769B2
(en)
|
2015-08-31 |
2022-03-22 |
Helixmith Co., Ltd |
Anti-Sialyl Tn chimeric antigen receptors
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
JP2018531229A
(ja)
|
2015-09-18 |
2018-10-25 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
癌の治療のための抗fugetactic剤の局所的送達
|
CN109310744A
(zh)
|
2015-09-23 |
2019-02-05 |
赛通免疫有限责任公司 |
用于免疫治疗的flt3定向car细胞
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
AU2016342041B2
(en)
|
2015-10-23 |
2021-12-02 |
Eureka Therapeutics, Inc. |
Antibody/T-cell receptor chimeric constructs and uses thereof
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
EP3368689B1
(de)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
US11001622B2
(en)
|
2015-11-19 |
2021-05-11 |
The Brigham And Women's Hospital, Inc. |
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
|
CN116334143A
(zh)
|
2015-11-23 |
2023-06-27 |
诺华股份有限公司 |
优化的慢病毒转移载体及其用途
|
US10946106B2
(en)
|
2015-11-30 |
2021-03-16 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
EP3393504A1
(de)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-hemmer zur kombinierten verwendung in der krebstherapie
|
WO2017117112A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
EP3397756B1
(de)
|
2015-12-30 |
2023-03-08 |
Novartis AG |
Immuneffektorzelltherapien mit verbesserter wirksamkeit
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
CN108699124A
(zh)
|
2016-01-21 |
2018-10-23 |
辉瑞大药厂 |
靶向表皮生长因子受体变体iii的嵌合抗原受体
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
CA3017766A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Nexgenia, Inc. |
Cell-surface molecule binding stimuli-responsive polymer compositions and methods
|
KR20230148844A
(ko)
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
CN113150170A
(zh)
|
2016-04-01 |
2021-07-23 |
凯德药业股份有限公司 |
嵌合受体及其方法和用途
|
TW202313671A
(zh)
|
2016-04-01 |
2023-04-01 |
美商凱特製藥公司 |
嵌合抗原和t細胞受體及使用方法
|
IL296966A
(en)
|
2016-04-01 |
2022-12-01 |
Amgen Inc |
Chimeric flt-3 receptors and methods of using them
|
KR102591930B1
(ko)
|
2016-04-01 |
2023-10-24 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
EP3443002A4
(de)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
Systeme für zurückgewonnene chimäre antigenrezeptoren
|
HRP20230457T1
(hr)
|
2016-04-15 |
2023-07-21 |
Novartis Ag |
Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
|
WO2017181101A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric alloantigen receptor t cells
|
EP3429633B1
(de)
|
2016-04-15 |
2021-02-24 |
Cellectis |
Verfahren zur herstellung von wirkstoffspezifischen überempfindlichen t-zellen zur immuntherapie mittels geninaktivierung
|
WO2017178586A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
WO2017192776A1
(en)
*
|
2016-05-03 |
2017-11-09 |
The Trustees Of Columbia University In The City Of New York |
Method for improving expansion of t cells from patients
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
WO2017201488A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
EP3464375A2
(de)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen
|
WO2017211900A1
(en)
|
2016-06-07 |
2017-12-14 |
Max-Delbrück-Centrum für Molekulare Medizin |
Chimeric antigen receptor and car-t cells that bind bcma
|
AU2017279548A1
(en)
|
2016-06-08 |
2018-12-13 |
Precigen, Inc. |
Cd33 specific chimeric antigen receptors
|
US11466291B2
(en)
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-01-25 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
AU2017299854A1
(en)
|
2016-07-18 |
2019-01-31 |
Helix Biopharma Corp. |
CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
|
WO2018018017A1
(en)
|
2016-07-21 |
2018-01-25 |
Berkeley Lights, Inc. |
Sorting of t lymphocytes in a microfluidic device
|
CN109790507A
(zh)
*
|
2016-07-26 |
2019-05-21 |
生物磁学解决方案有限责任公司 |
同时分离和活化血液制品中的t细胞以及随后的刺激扩增
|
US20190151365A1
(en)
|
2016-07-28 |
2019-05-23 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
JP7109789B2
(ja)
|
2016-08-02 |
2022-08-01 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US10294454B2
(en)
*
|
2016-08-24 |
2019-05-21 |
General Electric Company |
Methods and kits for cell activation
|
WO2018039637A1
(en)
|
2016-08-26 |
2018-03-01 |
Juno Therapeutics, Inc. |
Methods of enumerating particles present in a cell composition
|
WO2018045177A1
(en)
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
CN109964126B
(zh)
*
|
2016-09-12 |
2022-12-27 |
伊索普莱克西斯公司 |
用于细胞治疗法和其他免疫治疗法的多重分析的系统和方法
|
EP3512541A1
(de)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech, Inc. |
Chimäre antigenrezeptoren mit bcma-spezifischen fibronectin-typ-iii-domänen und verwendungen davon
|
EP3515475B1
(de)
|
2016-09-21 |
2024-05-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Gegen ccr4 chemokinrezeptor ccr4 gerichteter chimärer antigenrezeptor (car) und dessen verwendung
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
JP2020503887A
(ja)
*
|
2016-10-24 |
2020-02-06 |
ジーピービー・サイエンティフィック・リミテッド・ライアビリティ・カンパニーGpb Scientific, Llc |
治療用の細胞および組成物の調製における決定論的横置換
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
AU2017362484B2
(en)
|
2016-11-17 |
2021-12-16 |
2Seventy Bio, Inc. |
TGFβ signal convertor
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
BR112019010602A2
(pt)
|
2016-11-23 |
2019-12-17 |
Harpoon Therapeutics Inc |
proteínas trispecíficas para psma e métodos de uso
|
CA3044659A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
CN110234343A
(zh)
|
2016-12-21 |
2019-09-13 |
T细胞受体治疗公司 |
用于治疗癌症的经工程改造t细胞
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
EP3346001A1
(de)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospezifische regulatorische t-zellpopulation mit zytotoxizität gegenüber b-zellen
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3568474A1
(de)
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulation der expression von polypeptiden über neue genschalterexpressionssysteme
|
EP3568468A4
(de)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
Gegen histon-h3-peptid/mhc-komplexe gerichtete konstrukte und verwendungen davon
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP4043485A1
(de)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
|
TWI805565B
(zh)
|
2017-01-27 |
2023-06-21 |
日商斯德武利姆股份有限公司 |
心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
|
EP3577134A1
(de)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Behandlung von krebs mit chimären t-zellrezeptorproteinen mit mehreren spezifitäten
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
US11311609B2
(en)
|
2017-02-08 |
2022-04-26 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
WO2018152181A1
(en)
|
2017-02-14 |
2018-08-23 |
Kite Pharma, Inc. |
Cd70 binding molecules and methods of use thereof
|
EP3589662A4
(de)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
Induzierbares monovalentes antigenbindendes protein
|
TW201837175A
(zh)
|
2017-03-13 |
2018-10-16 |
美商凱特製藥公司 |
用於黑色素瘤之嵌合抗原受體及其用途
|
CA3056542A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
JP2020515542A
(ja)
|
2017-03-23 |
2020-05-28 |
ザ ジェネラル ホスピタル コーポレイション |
Cxcr4/cxcr7の遮断およびヒトパピローマウイルス関連疾患の治療
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018178378A1
(en)
|
2017-03-31 |
2018-10-04 |
Cellectis Sa |
New universal chimeric antigen receptor t cells specific for cd22
|
EP3606518A4
(de)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
|
WO2018187332A1
(en)
|
2017-04-03 |
2018-10-11 |
Kite Pharma, Inc. |
Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
|
EP3610266A4
(de)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
Tumorsignatur für metastasen, zusammensetzungen von substanzen und verwendung davon
|
US11767512B2
(en)
|
2017-04-13 |
2023-09-26 |
Cellectis |
Sequence specific reagents targeting CCR5 in primary hematopoietic cells
|
CA3057265A1
(en)
|
2017-04-19 |
2018-10-25 |
Allogene Therapeutics, Inc. |
Improved t cell compositions and methods
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
MY201065A
(en)
|
2017-04-26 |
2024-02-01 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
CN110741016A
(zh)
|
2017-04-26 |
2020-01-31 |
优瑞科生物技术公司 |
嵌合抗体/t-细胞受体构筑体及其用途
|
EP3615055A1
(de)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
メソテリン結合タンパク質
|
WO2018206791A1
(en)
|
2017-05-12 |
2018-11-15 |
Cellectis |
Protease based switch chimeric antigen receptors for safer cell immunotherapy
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
AU2018268087B2
(en)
|
2017-05-18 |
2022-03-17 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
KR102426447B1
(ko)
|
2017-05-26 |
2022-07-29 |
카이트 파마 인코포레이티드 |
배아 중간엽 전구 세포를 제조하고 사용하는 방법
|
SG10202108528QA
(en)
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
CN110997920A
(zh)
|
2017-06-07 |
2020-04-10 |
英特拉克森公司 |
新型细胞标签的表达
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
EA202090149A1
(ru)
|
2017-06-28 |
2020-05-31 |
Ридженерон Фармасьютикалз, Инк. |
Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
|
WO2019002633A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
|
WO2019018402A2
(en)
|
2017-07-17 |
2019-01-24 |
Janssen Biotech, Inc. |
ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
SG11202000425QA
(en)
*
|
2017-07-21 |
2020-02-27 |
Berkeley Lights Inc |
Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof
|
CA3072859A1
(en)
|
2017-08-23 |
2019-02-28 |
Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinscht |
Chimeric antigen receptor and car-t cells that bind cxcr5
|
AU2018338423A1
(en)
|
2017-09-20 |
2020-04-09 |
Sangamo Therapeutics France |
Novel anti-HLA-A2 antibodies and uses thereof
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
KR20200063215A
(ko)
|
2017-10-06 |
2020-06-04 |
오슬로 유니버시테시케후스 에이치에프 |
키메라 항원 수용체
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
BR112020007196A2
(pt)
|
2017-10-13 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
proteínas triespecíficas e métodos de uso
|
CR20200195A
(es)
|
2017-10-13 |
2020-08-14 |
Harpoon Therapeutics Inc |
Proteínas de unión a antigenos de maduraciòn de celulas b
|
AR113777A1
(es)
|
2017-10-18 |
2020-06-10 |
Kite Pharma Inc |
Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos
|
EP3684919A1
(de)
|
2017-10-19 |
2020-07-29 |
Cellectis |
Gezielte genintegration von nk-inhibitor-genen für eine verbesserte immunzellentherapie
|
CA3078270A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
CA3079096A1
(en)
|
2017-11-01 |
2019-05-09 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
JP7357613B2
(ja)
|
2017-11-06 |
2023-10-06 |
ラディック インスティテュート フォア キャンサー リサーチ リミテッド |
リンパ球の拡大方法
|
EP3710039A4
(de)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
EP3717907A1
(de)
|
2017-11-30 |
2020-10-07 |
Novartis AG |
Gegen bcma gerichteter chimärer antigenrezeptor und verwendungen davon
|
EP3718561A4
(de)
|
2017-12-01 |
2021-07-21 |
Stemrim Inc. |
Therapeutikum für entzündliche darmerkrankung
|
US20200384104A1
(en)
*
|
2017-12-15 |
2020-12-10 |
Northwestern University |
Structure-Function Relationships in the Development of Immunotherapeutic Agents
|
WO2019126146A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Xcell Biosciences, Inc. |
Methods of modulating cell phenotype by way of regulating the gaseous environment
|
JP6744906B2
(ja)
|
2017-12-22 |
2020-08-19 |
財團法人工業技術研究院Industrial Technology Research Institute |
免疫細胞のインビトロ活性化および/または増殖の方法
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
ES2908324T3
(es)
|
2018-01-12 |
2022-04-28 |
Curocell Inc |
Células inmunes mejoradas utilizando ARNsh doble y composición que las incluye
|
JP2021510738A
(ja)
|
2018-01-15 |
2021-04-30 |
ファイザー・インク |
4−1bbと組み合わせたキメラ抗原受容体免疫治療製品の投与方法
|
EP3694546A1
(de)
|
2018-01-30 |
2020-08-19 |
Cellectis |
Kombination aus allogenen immunzellen, die für ein antigen defizient sind, das sowohl auf t-zellen als auch pathologischen zellen präsent ist, und therapeutischer antikörper gegen das besagte antigen
|
WO2019152440A1
(en)
|
2018-01-30 |
2019-08-08 |
Foghorn Therapeutics Inc. |
Methods and compounds for treating disorders
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
BR112020015641A2
(pt)
|
2018-02-01 |
2021-01-05 |
Pfizer Inc. |
Anticorpos específicos para cd70 e seus usos
|
TW201936633A
(zh)
|
2018-02-01 |
2019-09-16 |
美商輝瑞大藥廠 |
標靶至cd70的嵌合抗原受體
|
EP3752203A1
(de)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
|
US20210040449A1
(en)
|
2018-02-16 |
2021-02-11 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
WO2019169194A1
(en)
|
2018-02-28 |
2019-09-06 |
Juno Therapeutics, Inc. |
Methods for detecting particles present in a cell composition
|
BR112020017734A2
(pt)
|
2018-03-02 |
2020-12-29 |
Allogene Therapeutics, Inc. |
Receptores de citocina quiméricos induzíveis
|
KR102495666B1
(ko)
|
2018-03-14 |
2023-02-06 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
EP3765094A4
(de)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
Genregulatorische zusammensetzungen und verfahren zur verbesserten immuntherapie
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
WO2019183455A1
(en)
|
2018-03-22 |
2019-09-26 |
Windmil Therapeutics, Inc. |
Prostate cancer specific marrow infiltrating lymphocytes and uses thereof
|
CA3095920A1
(en)
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
CA3096401A1
(en)
|
2018-04-12 |
2019-10-17 |
Kite Pharma, Inc. |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
WO2019197678A1
(en)
|
2018-04-13 |
2019-10-17 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
EP3781590A1
(de)
|
2018-04-20 |
2021-02-24 |
Medizinische Hochschule Hannover |
Chimärer antigenrezeptor und car-t zellen, die ein herpesvirus-antigen binden
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
EP3784351A1
(de)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car-t-zelltherapien mit erhöhter wirksamkeit
|
EP3788369A1
(de)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
|
US20210115378A1
(en)
*
|
2018-05-09 |
2021-04-22 |
Yale University |
Compositions and systems for ex vivo cell modulation and methods of use thereof
|
WO2019217913A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
EP3790629A1
(de)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Verfahren und zusammensetzungen zur behandlung von krebs
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
JP2021526795A
(ja)
|
2018-06-05 |
2021-10-11 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
筋特異的キナーゼキメラ自己受容体細胞の組成物および方法
|
EP3806962A1
(de)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma-chimäre antigenrezeptoren und verwendungen davon
|
EP4365194A2
(de)
|
2018-06-14 |
2024-05-08 |
2seventy bio, Inc. |
Cd79a-chimäre antigenrezeptoren
|
WO2019241549A1
(en)
|
2018-06-15 |
2019-12-19 |
A2 Biotherapeutics, Inc. |
Foxp3-expressing car-t regulatory cells
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
US20210155941A1
(en)
|
2018-06-22 |
2021-05-27 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
WO2020007593A1
(en)
|
2018-07-02 |
2020-01-09 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
BR112021000249A2
(pt)
|
2018-07-11 |
2021-04-06 |
Celgene Corporation |
Usos de receptores de antígeno quimérico anti-bcma
|
KR20210033025A
(ko)
|
2018-07-18 |
2021-03-25 |
암젠 인크 |
Steap1에 대한 키메라 수용체 및 이의 사용 방법
|
KR20210035832A
(ko)
|
2018-07-19 |
2021-04-01 |
리제너론 파아마슈티컬스, 인크. |
Bcma 특이성을 갖는 키메라 항원 수용체 및 이의 용도
|
SG11202101014XA
(en)
|
2018-08-02 |
2021-02-25 |
Kite Pharma Inc |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
AU2019318135A1
(en)
|
2018-08-10 |
2021-03-04 |
Sangamo Therapeutics France |
New car constructs comprising TNFR2 domains
|
KR102543325B1
(ko)
|
2018-08-13 |
2023-06-13 |
루트패스 제노믹스, 인크. |
쌍을 이룬 이분 면역수용체 폴리뉴클레오티드의 고처리량 클로닝 및 이의 적용
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
MX2021002225A
(es)
|
2018-08-30 |
2021-07-16 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
AU2019328677A1
(en)
|
2018-08-31 |
2021-04-01 |
Invectys SA |
Chimeric antigen receptors against multiple HLA-G isoforms
|
CA3112813A1
(en)
*
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
EP3856782A1
(de)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Chimärer cd19-antigen-rezeptor (car) und cd22-car-kombinationstherapien
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
CN113015750A
(zh)
|
2018-11-07 |
2021-06-22 |
克里斯珀医疗股份公司 |
抗liv1免疫细胞癌症疗法
|
US20210290678A1
(en)
|
2018-11-07 |
2021-09-23 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
SG11202103832SA
(en)
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
CA3118757A1
(en)
|
2018-11-08 |
2020-05-14 |
Neximmune, Inc. |
T cell compositions with improved phenotypic properties
|
EP3880307A1
(de)
|
2018-11-14 |
2021-09-22 |
Fundación Pública Andaluza Progreso Y Salud |
Polynukleotid für sicherere und wirksamere immuntherapien
|
EP3887507A1
(de)
|
2018-11-30 |
2021-10-06 |
Janssen Biotech, Inc. |
Gamma-delta-t-zellen und verwendungen davon
|
SG11202106049RA
(en)
|
2018-12-10 |
2021-07-29 |
Amgen Inc |
Mutated piggybac transposase
|
WO2020123691A2
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc |
Chimeric antigen and t cell receptors and methods of use
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
GB201900858D0
(en)
|
2019-01-22 |
2019-03-13 |
Price Nicola Kaye |
Receptors providing targeted costimulation for adoptive cell therapy
|
US20230066136A1
(en)
|
2019-01-29 |
2023-03-02 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
US20220143084A1
(en)
|
2019-02-15 |
2022-05-12 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
EP3927371A1
(de)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
|
PE20220495A1
(es)
|
2019-03-01 |
2022-04-07 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3
|
MX2021010323A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos bicíclicos de heterociclilo y usos de este.
|
SG11202109036WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
EP3935151A1
(de)
|
2019-03-08 |
2022-01-12 |
Klinikum der Universität München |
Anti-csf1r-car-exprimierende lymphozyten für gezielte tumortherapie
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
CA3199205A1
(en)
|
2019-03-15 |
2020-09-24 |
Cartesian Therapeutics, Inc. |
Anti-bcma chimeric antigen receptors
|
EP3942023A1
(de)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
|
US20220154191A1
(en)
|
2019-03-25 |
2022-05-19 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
WO2020198413A1
(en)
|
2019-03-27 |
2020-10-01 |
The Trustees Of The University Of Pennsylvania |
Tn-muc1 chimeric antigen receptor (car) t cell therapy
|
WO2020206238A2
(en)
|
2019-04-05 |
2020-10-08 |
Rootpath Genomics, Inc. |
Compositions and methods for t-cell receptor gene assembly
|
WO2020206061A1
(en)
|
2019-04-05 |
2020-10-08 |
Bluebird Bio, Inc. |
Manufacturing anti-bcma car t cells
|
BR112021019571A2
(pt)
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
AU2020263495A1
(en)
|
2019-04-26 |
2021-10-28 |
Allogene Therapeutics, Inc. |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
CN113748201A
(zh)
|
2019-04-26 |
2021-12-03 |
艾洛基治疗公司 |
制备同种异体car t细胞的方法
|
CA3138707A1
(en)
|
2019-05-03 |
2020-11-12 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
MA55887A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Microarn de cellules immunitaires exprimés de manière différentielle pour la régulation de l'expression de protéines
|
AU2020275002A1
(en)
|
2019-05-14 |
2021-12-23 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
CA3138353A1
(en)
*
|
2019-05-16 |
2020-11-19 |
CyteQuest, Inc. |
Devices, methods, and systems for electroporation
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
EP3980458A1
(de)
|
2019-06-05 |
2022-04-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Chimärer autoantikörperrezeptor (caar), der autoantikörper gegen das zentrale nervensystem bei neurologischen autoimmunerkrankungen bindet
|
JP2022538836A
(ja)
|
2019-06-27 |
2022-09-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
がんを治療するためのキメラ抗原受容体t細胞及びnk細胞阻害剤の使用
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
CN110387058A
(zh)
*
|
2019-07-24 |
2019-10-29 |
南通大学 |
一种促进细胞在水凝胶上面正常生长的方法
|
MX2022000896A
(es)
|
2019-07-24 |
2022-02-14 |
Regeneron Pharma |
Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20220305056A1
(en)
|
2019-08-27 |
2022-09-29 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
BR112022003891A2
(pt)
|
2019-09-06 |
2022-05-31 |
Crispr Therapeutics Ag |
Células t geneticamente manipuladas possuindo persistência melhorada em cultura
|
EP4028064A1
(de)
|
2019-09-12 |
2022-07-20 |
The Broad Institute, Inc. |
Manipulierte adeno-assoziierte viruskapside
|
EP4031178A1
(de)
|
2019-09-16 |
2022-07-27 |
Surface Oncology, Inc. |
Anti-cd39-antikörperzusammensetzungen und verfahren
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
EP4034561A2
(de)
|
2019-09-27 |
2022-08-03 |
Starkage Therapeutics |
Mit seneszenten zellen assoziierte antigen-bindende domänen, antikörper und chimäre antigenrezeptoren damit sowie deren verwendungen
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
EP3808766A1
(de)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
|
CA3160142A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
CA3160178A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
CA3159387A1
(en)
|
2019-11-08 |
2021-05-14 |
Kiyatec, Inc. |
Methods of screening to determine effective dosing of cancer therapeutics
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
WO2021096868A1
(en)
|
2019-11-12 |
2021-05-20 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
US11975026B2
(en)
|
2019-11-26 |
2024-05-07 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
CA3161112A1
(en)
|
2019-12-11 |
2021-06-17 |
Carl Alexander Kamb |
Lilrb1-based chimeric antigen receptor
|
EP4081537A1
(de)
|
2019-12-23 |
2022-11-02 |
Cellectis |
Neue mesothelin-spezifische chimäre antigen-rezeptoren (car) für die krebsimmuntherapie bei soliden tumoren
|
CN113025570A
(zh)
*
|
2019-12-24 |
2021-06-25 |
华东数字医学工程研究院 |
一种t细胞增殖方法及其用途
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
EP4087611A1
(de)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2-inhibitordosierung und verfahren zum behandeln von krebs
|
CN115315273A
(zh)
|
2020-01-14 |
2022-11-08 |
辛德凯因股份有限公司 |
Il-2直向同源物及其使用方法
|
JP2023512469A
(ja)
|
2020-01-17 |
2023-03-27 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌療法におけるbcma特異的キメラ抗原受容体を発現する遺伝子改変t細胞及びその使用
|
CN115427436A
(zh)
|
2020-01-24 |
2022-12-02 |
里珍纳龙药品有限公司 |
黑素瘤优先表达抗原(prame)t细胞受体及其使用方法
|
CN115052594A
(zh)
|
2020-01-29 |
2022-09-13 |
福宏治疗公司 |
化合物和其用途
|
EP3862032A1
(de)
*
|
2020-02-07 |
2021-08-11 |
Micell Technologies, Inc. |
Stents mit biologisch abbaubaren schichten
|
EP4104187A1
(de)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie
|
CN115768463A
(zh)
|
2020-02-21 |
2023-03-07 |
哈普恩治疗公司 |
Flt3结合蛋白及使用方法
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CR20220431A
(es)
|
2020-03-03 |
2023-02-21 |
Janssen Biotech Inc |
CÉLULAS T yo Y USOS DE ESTAS
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
CN115315446A
(zh)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
抗糖-cd44抗体及其用途
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
AU2021243864A1
(en)
|
2020-03-27 |
2022-11-03 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
EP4135851A1
(de)
|
2020-04-17 |
2023-02-22 |
City of Hope |
Gegen flt3 gerichtete chimäre antigenrezeptormodifizierte zellen zur behandlung von flt3-positiven malignomen
|
WO2021222576A1
(en)
|
2020-05-01 |
2021-11-04 |
A2 Biotherapeutics, Inc. |
Pag1 fusion proteins and methods of making and using same
|
IL297874A
(en)
|
2020-05-05 |
2023-01-01 |
Regeneron Pharma |
Car containing cd28 zeta and cd3 zeta
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Zbtb32阻害剤及びその使用
|
WO2021252635A1
(en)
|
2020-06-11 |
2021-12-16 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
EP4182336A1
(de)
|
2020-07-17 |
2023-05-24 |
Instil Bio (Uk) Limited |
Chimäre moleküle zur gezielten costimulation für adoptive zelltherapie
|
EP4182338A1
(de)
|
2020-07-17 |
2023-05-24 |
Instil Bio (Uk) Limited |
Rezeptoren zur gezielten costimulation für adoptive zelltherapie
|
US20220023346A1
(en)
|
2020-07-21 |
2022-01-27 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
EP4185616A1
(de)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-zellen zur expression von immunzell-engagern in allogenen einstellungen
|
US11787800B2
(en)
|
2020-07-29 |
2023-10-17 |
Foghorn Therapeutics Inc. |
BRD9 degraders and uses thereof
|
MX2023001556A
(es)
|
2020-08-05 |
2023-03-08 |
Dragonfly Therapeutics Inc |
Anticuerpos que se dirigen a egfr y uso de los mismos.
|
EP4196493A1
(de)
|
2020-08-13 |
2023-06-21 |
A2 Biotherapeutics, Inc. |
Genfusionen zur kontrolle genetisch modifizierter zellen
|
IL299911A
(en)
|
2020-08-14 |
2023-03-01 |
Kite Pharma Inc |
Improving immune cell function
|
IL300500A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of mesothelin positive cancer
|
TW202214846A
(zh)
|
2020-08-20 |
2022-04-16 |
美商A2生物治療學股份有限公司 |
用於治療egfr陽性癌症之組合物及方法
|
IL300497A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Compositions and methods for treating CEACAM-positive cancer
|
EP4199959A1
(de)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
Chimäres antigenrezeptorkonstrukt, das für ein checkpoint-hemmendes molekül und ein immunstimulatorisches zytokin codiert, und car-exprimierende zellen, die cd44v6 erkennen
|
EP4199958A1
(de)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
Chimäre antigenrezeptor(car)-exprimierende zellen zur cea-erkennung
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
EP4215609A1
(de)
|
2020-09-21 |
2023-07-26 |
Fundación Pública Andaluza Progreso Y Salud |
Polynukleotid zur physiologischen expression in t-zellen
|
US20220090015A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with multiplex and localized activity
|
EP4176048A1
(de)
|
2020-09-23 |
2023-05-10 |
CRISPR Therapeutics AG |
Genetisch veränderte t-zellen mit regnase-1 und/oder tgfbrii-unterbrechung mit verbesserter funktionalität und persistenz
|
KR20230113755A
(ko)
|
2020-11-04 |
2023-08-01 |
셀진 코포레이션 |
선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
JP2023552773A
(ja)
|
2020-12-04 |
2023-12-19 |
セルジーン コーポレーション |
炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体(car)t細胞療法の使用
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
US20220227832A1
(en)
|
2020-12-21 |
2022-07-21 |
Allogene Therapeutics, Inc. |
Protease-activating cd45-gate car
|
WO2022136503A1
(en)
|
2020-12-22 |
2022-06-30 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
EP4019538A1
(de)
|
2020-12-22 |
2022-06-29 |
Charité - Universitätsmedizin Berlin |
Umprogrammierung von immunzellen durch gezielte integration von zeta-defizitären chimären antigen-rezeptor-transgenen
|
AU2021405062A1
(en)
|
2020-12-23 |
2023-07-06 |
Gadeta B.V. |
Chimeric, transmembrane proteins with bidirectional signalling activity
|
US20220193134A1
(en)
|
2020-12-23 |
2022-06-23 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
US20220202859A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
KR20230129485A
(ko)
|
2021-01-10 |
2023-09-08 |
카이트 파마 인코포레이티드 |
T 세포 요법
|
CN116997563A
(zh)
|
2021-01-27 |
2023-11-03 |
莱尔免疫制药股份有限公司 |
改良的免疫细胞疗法
|
IL303847A
(en)
|
2021-01-28 |
2023-08-01 |
Allogene Therapeutics Inc |
Methods for transferring immune cells
|
KR20230157315A
(ko)
|
2021-01-28 |
2023-11-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
|
MX2023008809A
(es)
|
2021-01-29 |
2023-08-04 |
Allogene Therapeutics Inc |
ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
|
JP2024507129A
(ja)
|
2021-02-16 |
2024-02-16 |
エー2 バイオセラピューティクス, インコーポレイテッド |
Her2陽性がんを治療するための組成物及び方法
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
WO2022187663A1
(en)
|
2021-03-04 |
2022-09-09 |
Allogene Therapeutics, Inc. |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
EP4305153A1
(de)
|
2021-03-09 |
2024-01-17 |
CRISPR Therapeutics AG |
Genetisch veränderte t-zellen mit ptpn2-knockout mit verbesserter funktionalität und antitumoraktivität
|
WO2022192439A1
(en)
|
2021-03-11 |
2022-09-15 |
Kite Pharma, Inc. |
Improving immune cell function
|
IL307493A
(en)
|
2021-04-08 |
2023-12-01 |
Janssen Biotech Inc |
Materials and methods for improved engineering of stem cell-like memory T cells
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
IL308012A
(en)
|
2021-04-30 |
2023-12-01 |
Cellectis Sa |
Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
KR20240004960A
(ko)
|
2021-05-05 |
2024-01-11 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
WO2022235832A1
(en)
|
2021-05-06 |
2022-11-10 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
TW202310870A
(zh)
|
2021-05-12 |
2023-03-16 |
瑞士商Crispr治療公司 |
用於治療造血惡性腫瘤之靶向cd70的基因工程化免疫細胞
|
AR125852A1
(es)
|
2021-05-12 |
2023-08-16 |
Crispr Therapeutics Ag |
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
|
US20220378830A1
(en)
|
2021-05-14 |
2022-12-01 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
EP4341391A1
(de)
|
2021-05-20 |
2024-03-27 |
Cellectis S.A. |
Gentherapie zur behandlung des hyper-ige-syndroms (hies) durch gezielte genintegration
|
EP4341300A1
(de)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Erhöhung der wirksamkeit von t-zell-vermittelter immuntherapie durch modulation von krebsassoziierten fibroblasten in soliden tumoren
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
AU2022292640A1
(en)
|
2021-06-15 |
2023-11-30 |
Allogene Therapeutics, Inc. |
Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
|
EP4355340A1
(de)
|
2021-06-16 |
2024-04-24 |
Instil Bio, Inc. |
Rezeptoren zur gezielten costimulation für adoptive zelltherapie
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
US11767330B2
(en)
|
2021-07-06 |
2023-09-26 |
Foghorn Therapeutics Inc. |
Citrate salt, pharmaceutical compositions, and methods of making and using the same
|
CN117980326A
(zh)
|
2021-07-14 |
2024-05-03 |
2赛文缇生物公司 |
与来自抗体的结合结构域融合的经工程化的t细胞受体
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
WO2023007373A1
(en)
|
2021-07-26 |
2023-02-02 |
Crispr Therapeutics Ag |
Methods for manufacturing genetically engineered car-t cells
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
WO2023017159A1
(en)
|
2021-08-13 |
2023-02-16 |
Ludwig-Maximilians-Universität München |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
KR20240049813A
(ko)
|
2021-08-24 |
2024-04-17 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
향상된 암 면역치료법을 위한 il-10 발현 세포
|
TW202325733A
(zh)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
抗醣化-lamp1抗體及其用途
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
US20230128917A1
(en)
|
2021-09-14 |
2023-04-27 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023081813A1
(en)
|
2021-11-05 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Zip cytokine receptors
|
WO2023081894A2
(en)
|
2021-11-08 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Pre-effector car-t cell gene signatures
|
WO2023084399A1
(en)
|
2021-11-09 |
2023-05-19 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
US20230346836A1
(en)
|
2021-12-22 |
2023-11-02 |
Crispr Therapeutics Ag |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023180968A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
WO2023192895A1
(en)
|
2022-03-29 |
2023-10-05 |
Allogene Therapeutics Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
EP4276174A1
(de)
|
2022-05-09 |
2023-11-15 |
Cellectis S.A. |
Gentherapie zur behandlung von aktiviertem pi3kinase-delta-syndrom typ 1 (apds1)
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
WO2023240182A1
(en)
|
2022-06-08 |
2023-12-14 |
St. Jude Children's Research Hospital, Inc. |
Disruption of kdm4a in t cells to enhance immunotherapy
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023242434A1
(en)
|
2022-06-17 |
2023-12-21 |
Gadeta B.V. |
Modified immune cells
|
WO2023248110A1
(en)
|
2022-06-20 |
2023-12-28 |
Crispr Therapeutics Ag |
Base editing proteins and uses thereof
|
WO2024003786A1
(en)
|
2022-06-29 |
2024-01-04 |
Crispr Therapeutics Ag |
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024010782A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024010784A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024020429A1
(en)
|
2022-07-22 |
2024-01-25 |
Lyell Immunopharma, Inc. |
Immune cell therapy
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
US20240042030A1
(en)
|
2022-07-29 |
2024-02-08 |
Allogene Therapeutics, Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
US20240091261A1
(en)
|
2022-08-26 |
2024-03-21 |
Kite Pharma, Inc. |
Immune cell function
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024059787A1
(en)
|
2022-09-16 |
2024-03-21 |
St. Jude Children's Research Hospital, Inc. |
Disruption of asxl1 in t cells to enhance immunotherapy
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|
EP4353252A1
(de)
|
2022-10-10 |
2024-04-17 |
Charité - Universitätsmedizin Berlin |
Antigenspezifische t-zellen durch geneditierung von cd3-epsilon
|
EP4353253A1
(de)
|
2022-10-10 |
2024-04-17 |
Charité - Universitätsmedizin Berlin |
Reinigung von tcr-modifizierten t-zellen unter verwendung tcr-spezifischer car-nk-zellen
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024092092A2
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for allogeneic immunotherapies
|
WO2024092227A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|